TIDMAPH
RNS Number : 6880A
Alliance Pharma PLC
25 May 2023
For immediate release 25 May 2023
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Result of AGM
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that, at its Annual General Meeting held earlier
today, all the resolutions, as set out in the Notice of Meeting,
were duly passed on a poll.
The number of the Group's shares in issue as at the date of the
meeting was 540,124,673 ordinary shares of 1p each.
The votes were as follows:
RESOLUTION VOTES FOR % VOTES AGAINST % VOTES WITHHELD*
================================= ============ ====== ============== ====== ================
1 Report and Accounts 219,104,625 80.85 51,908,041 19.15 101,986,122
2 Final dividend 233,018,515 62.48 139,907,211 37.52 73,062
3 Elect J. Heper 264,206,888 92.73 20,714,828 7.27 88,077,072
4 Elect M. Sutherland 233,010,074 81.78 51,908,621 18.22 88,080,093
5 Re-elect P. Butterfield 222,069,893 77.94 62,848,802 22.06 88,080,093
6 Re-elect A. Franklin 264,044,516 92.67 20,874,179 7.33 88,080,093
7 Re-elect R. Jones 201,039,250 70.56 83,879,445 29.44 88,080,093
8 Re-elect J. LeCouilliard 206,081,209 77.31 60,470,644 22.69 106,446,935
9 Re-elect K. Neirynck 253,533,764 88.98 31,387,952 11.02 88,077,072
10 Appoint Auditor 284,909,887 99.99 7,118 0.01 88,081,783
11 Remuneration of Auditor 284,912,231 99.99 4,328 0.01 88,082,229
179,118,
12 Allot shares - general 371 62.87 105,800,885 37.13 88,079,532
13 Allot shares - additional 178,986,132 62.82 105,933,124 37.18 88,079,532
Disapply pre-emption rights
14 - general 228,436,470 80.18 56,483,517 19.82 88,078,801
Disapply pre-emption rights
15 - additional 228,318,841 80.13 56,601,146 19.87 88,078,801
The Board notes the votes against Resolutions 2, 5, 7, 8, 12 and
13 and will consult with shareholders to understand their views and
publish the results of that consultation in due course.
Chris Chrysanthou
Group General Counsel & Company Secretary
25 May 2023
*Each share carries one vote and a 'vote withheld' is not a vote
in law and has not been counted in the calculation of the
proportion of the votes for and against the resolution. Any proxy
appointments which gave discretion to the Chairman have been
included in the 'votes for' total.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
Buchanan + 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser
and Corporate Broking) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher
Shah
Investec Bank plc + 44 (0)20 7597 5970
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company. Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEEFFIEDSELI
(END) Dow Jones Newswires
May 25, 2023 07:44 ET (11:44 GMT)
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mag 2023 a Mag 2024
